A Letter from the Desk of CBIH
Cannabis Bioscience International Holdings (CBIH) CEO Dante Picazo represented the company at DEA Hearing Docket No. 1362 and 24-44 regarding cannabis reclassification. The hearings involve 20 groups debating the potential rescheduling of cannabis from Schedule I to Schedule III. The proposed change could enable advanced medical research, treatment development, and economic growth.
CBIH is seeking expert witnesses, including patients with multiple sclerosis and epilepsy, medical experts, and legal professionals, to participate in the next DEA Hearing. The deadline for participation is December 11, 5:00 PM CT. The company emphasizes that failure to achieve reclassification could delay further discussions for 8-10 years.
Cannabis Bioscience International Holdings (CBIH) ha rappresentato la compagnia durante l'udienza del DEA Docket No. 1362 e 24-44 riguardante la riclassificazione della cannabis. Le udienze coinvolgono 20 gruppi che discutono il potenziale riposizionamento della cannabis da Schedule I a Schedule III. Il cambiamento proposto potrebbe consentire avanzate ricerche mediche, sviluppo di trattamenti e crescita economica.
CBIH sta cercando testimoni esperti, inclusi pazienti con sclerosi multipla ed epilessia, esperti medici e professionisti legali, per partecipare alla prossima udienza del DEA. La scadenza per la partecipazione è il 11 dicembre, alle 17:00 CT. L'azienda sottolinea che il mancato conseguimento della riclassificazione potrebbe ritardare ulteriori discussioni per 8-10 anni.
Cannabis Bioscience International Holdings (CBIH) representó a la compañía en la audiencia del DEA Docket No. 1362 y 24-44 sobre la reclasificación de la cannabis. Las audiencias involucran 20 grupos debatiendo la posible reprogramación de la cannabis de la Lista I a la Lista III. El cambio propuesto podría permitir investigaciones médicas avanzadas, desarrollo de tratamientos y crecimiento económico.
CBIH está buscando testigos expertos, incluidos pacientes con esclerosis múltiple y epilepsia, expertos médicos y profesionales legales, para participar en la próxima audiencia de la DEA. La fecha límite para participar es el 11 de diciembre, a las 5:00 PM CT. La compañía enfatiza que no lograr la reclasificación podría retrasar más discusiones por 8-10 años.
캐나비스 바이오사이언스 인터내셔널 홀딩스 (CBIH)의 CEO 단테 피카조는 DEA 청문회 Docket No. 1362 및 24-44에서 대마초 재분류에 대해 회사를 대표했습니다. 이 청문회에는 대마초를 Schedule I에서 Schedule III로 재조정하는 것에 대한 20개 그룹의 논의가 포함됩니다. 제안된 변화는 고급 의료 연구, 치료 개발 및 경제 성장의 가능성을 열어줄 수 있습니다.
CBIH는 다발성 경화증 및 간질 환자, 의료 전문가 및 법률 전문가를 포함한 전문가 증인을 다음 DEA 청문회에 초대하고 있습니다. 참여 마감일은 12월 11일 오후 5시 CT입니다. 이 회사는 재분류에 실패할 경우 향후 논의가 8-10년 간 지연될 수 있음을 강조합니다.
Cannabis Bioscience International Holdings (CBIH) a représenté l’entreprise lors de l’audience du DEA Docket No. 1362 et 24-44 concernant la reclassification du cannabis. Les audiences impliquent 20 groupes débattant de la possibilité de reclasser le cannabis de la Liste I à la Liste III. Le changement proposé pourrait permettre des recherches médicales avancées, le développement de traitements et la croissance économique.
CBIH recherche des témoins experts, y compris des patients atteints de sclérose en plaques et d'épilepsie, des professionnels de la santé et des experts juridiques, pour participer à la prochaine audience du DEA. La date limite de participation est le 11 décembre à 17h00 CT. L'entreprise souligne que le non-respect de cette reclassification pourrait retarder les discussions ultérieures de 8 à 10 ans.
Cannabis Bioscience International Holdings (CBIH) CEO Dante Picazo vertrat das Unternehmen bei der DEA-Anhörung Docket Nr. 1362 und 24-44 zur Neuordnung von Cannabis. Bei den Anhörungen diskutieren 20 Gruppen über die mögliche Umgruppierung von Cannabis von Schedule I auf Schedule III. Die vorgeschlagene Änderung könnte fortgeschrittene medizinische Forschung, Behandlungsmöglichkeiten und wirtschaftliches Wachstum ermöglichen.
CBIH sucht Expertenzeugenaussagen, darunter Patienten mit Multipler Sklerose und Epilepsie, medizinische Experten und juristische Fachkräfte, um an der nächsten DEA-Anhörung teilzunehmen. Die Frist für die Teilnahme ist der 11. Dezember um 17:00 Uhr CT. Das Unternehmen betont, dass das Versäumnis, eine Neuordnung zu erreichen, weitere Diskussionen um 8-10 Jahre verzögern könnte.
- Potential cannabis rescheduling from Schedule I to III could open new business opportunities
- Company actively participating in regulatory proceedings that could expand market access
- Significant opposition expected from government and major law firms
- Risk of 8-10 year delay if reclassification effort fails
- Need for substantial legal and scientific support over next three months indicates significant resource requirements
HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings
Dear Community,
On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility.
CBIH remains committed to actively participating in these hearings, which represent a crucial moment for the future of cannabis in medical and scientific advancement. The discussions include at least 20 groups, 10 in opposition and 10 in support, highlighting the intense debate surrounding this critical issue.
The proposed reclassification of cannabis from Schedule I to Schedule III could usher in transformative changes. It would pave the way for advanced research, facilitate the development of safe and effective treatments for chronic and hard-to-treat conditions, and significantly improve the quality of life for patients. Beyond medicine, this change could drive economic growth by creating jobs, attracting investment, supporting small businesses, and providing a boost to the national economy.
This is a once-in-a-lifetime opportunity, and we must recognize its magnitude. If the reclassification effort does not succeed, we may not have another chance to revisit this discussion for another 8–10 years. That is why I am calling on all stakeholders, patients willing to share their stories, especially those with multiple sclerosis and epilepsy who have found relief through medical cannabis, medical experts who can validate cannabis’s therapeutic benefits, and legal professionals equipped to navigate this complex process, to join us in this crucial mission and participate as one of CBIH’s expert witnesses in the next DEA Hearing.
Time is of the essence. We have just a narrow window to act, with a deadline of Wednesday, December 11, at 5:00 PM CT, to assemble our team of contributors. Over the next three months, we will require robust legal and scientific support to counter significant opposition, including government testimony and representation from major law firms. The expertise and participation of people who understand the necessity of this reclassification can make a meaningful difference in ensuring that we advocate effectively for this vital cause.
If you are a scientist, medical expert, patient, or legal professional and wish to contribute to this effort, please contact us via email at ir@cbih.net.
The reclassification of cannabis is more than a policy change, it is an opportunity to revolutionize quality of life, stimulate economic growth, and open doors to innovation. Please keep in mind that if Americans want cannabis to be reclassified from Schedule I to III, we are going to have to fight for it.
Thank you for your support.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
FAQ
What is CBIH's role in the DEA cannabis reclassification hearings?
What is the deadline for expert witnesses to join CBIH's DEA hearing team?
What could happen if the cannabis reclassification effort fails for CBIH?
